Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

10,210 total articles

Director's Stock Sales at Neurocrine Biosciences Occur Amid Strong Quarterly Performance and Valuation Interest

Director's Stock Sales at Neurocrine Biosciences Occur Amid Strong Quarterly Performance and Valuation Interest

Neurocrine Biosciences Inc.'s (NASDAQ:NBIX) director, Leslie V. Norwalk, sold shares totaling $590,601 on May 12, 2026. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan, occurred while the company reported strong first quarter results for 2026. The Q1 earnings report showed EPS of $1.94 against an expected $1.17, and revenue…

Capital One Executive Sale Details and Broader Market Indicators

Capital One Executive Sale Details and Broader Market Indicators

Chief Human Resources Officer Kaitlin Haggerty recently reported the sale of company common stock totaling $262,124 for Capital One Financial Corp. The transaction spanned May 12 and May 13, 2026. This activity occurred alongside other recent corporate disclosures, including Q1 2026 earnings which saw adjusted EPS falling below forecasts, coupled w…

Director's Sale at DexCom Amid Valuation and Growth Signals

Director's Sale at DexCom Amid Valuation and Growth Signals

DexCom director Bridgette P. Heller sold a block of common stock on May 12, 2026, valued at $60,730. This sale occurred while the stock was trading near its 52-week low. However, recent operational data and institutional activity point to strong underlying fundamentals for DexCom, including robust Q1 revenue growth and multiple price target increas…

i3 Verticals CEO Gregory Daily Purchases Shares Amid Price Dip

i3 Verticals CEO Gregory Daily Purchases Shares Amid Price Dip

Gregory S. Daily, CEO of i3 Verticals, Inc., recently purchased a significant block of the company's common stock. This transaction occurs while the stock is trading near its 52-week low following a decline over the last week. While recent earnings for fiscal Q2 2026 exceeded expectations, several major financial institutions have simultaneously lo…

Analyst Eye Stock Movement Following CEO Insider Sale Amid Positive Clinical and Financial Developments at Cytokinetics

Analyst Eye Stock Movement Following CEO Insider Sale Amid Positive Clinical and Financial Developments at Cytokinetics

The recent transactions involving Cytokinetics, Inc. (NASDAQ:CYTK) reveal a mix of insider activity and significant corporate financial maneuvers. CEO Robert I. Blum sold a notable block of shares on May 14, 2026, while the company simultaneously completed a large stock offering and announced another planned offering. These activities are occurring…